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Anon-coding hexanucleotide repeat expansion in the
C9ORF72 gene is themost commonmutation associ-
ated with familial amyotrophic lateral sclerosis (ALS)
and frontotemporal dementia (FTD). To investigate
the pathological role of C9ORF72 in these diseases,
we generated a line of mice carrying a bacterial artifi-
cial chromosome containing exons 1 to 6 of the hu-
man C9ORF72 gene with approximately 500 repeats
of the GGGGCC motif. The mice showed no overt
behavioral phenotype but recapitulated distinctive
histopathological features of C9ORF72 ALS/FTD,
including sense and antisense intranuclear RNA foci
and poly(glycine-proline) dipeptide repeat proteins.
Finally, using an artificial microRNA that targets hu-
manC9ORF72 in cultures of primary cortical neurons
from the C9BAC mice, we have attenuated expres-
sion of the C9BAC transgene and the poly(GP) dipep-
tides. The C9ORF72 BAC transgenic mice will be a
valuable tool in the study of ALS/FTD pathobiology
and therapy.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative dis-
ease that primarily affects motor neurons in the motor cortex,
brainstem, and spinal cord; frontotemporal dementia (FTD) is
caused by the degeneration of neurons in the fronto-temporal re-
gions. Some individuals develop ALS and FTD simultaneously.902 Neuron 88, 902–909, December 2, 2015 ª2015 Elsevier Inc.Our understanding of these diseases was transformed by the
identification in some ALS/FTD cases of an abnormally
expanded GGGGCC repeat motif within the gene chromosome
9 open reading frame 72 (C9ORF72) (DeJesus-Hernandez
et al., 2011; Gijselinck et al., 2012; Renton et al., 2011). Now
recognized as the most common cause of dominantly inherited
ALS and FTD (c9ALS/FTD), the C9ORF72 GGGGCC motif can
be expanded to several thousand repeats in affected individuals
(Majounie et al., 2012).
The normal function of the C9ORF72 product is unknown,
though a role in membrane trafficking has been suggested
(Farg et al., 2014). Decreased levels of C9ORF72 transcripts
have been described in c9ALS/FTD patient tissues and derived
cell lines (Belzil et al., 2013; DeJesus-Hernandez et al., 2011),
suggesting that haploinsufficiency might contribute to disease.
It is also likely that the intronic C9ORF72 repeat expansion con-
fers one or more toxic properties that compromise neuron
viability. Bidirectional transcription of the mutated C9ORF72
generates GGGGCC sense and CCCCGG antisense repeat-
containing RNA transcripts that form intranuclear RNA foci
(Mizielinska et al., 2013) and potentially sequester RNA binding
proteins (Cooper-Knock et al., 2014). The expanded RNA tran-
scripts also undergo repeat-associated non-ATG (RAN) transla-
tion, a non-canonical mechanism of protein synthesis that yields
aggregation-prone dipeptide repeat (DPR) proteins that form
cytoplasmic inclusion bodies (Ash et al., 2013; Mori et al.,
2013; Zu et al., 2011).
Model systems that recapitulate thepathobiologyof themutant
C9ORF72geneareparticularly helpful in understanding howsuch
mutations cause neurodegeneration in vivo. Several invertebrate
(Mizielinska and Isaacs, 2014; Therrien et al., 2013; Tran et al.,
2015), vertebrate (Ciura et al., 2013; Chew et al., 2015), and pa-
tient-derived cell models (Almeida et al., 2013; Donnelly et al.,
2013; Lagier-Tourenne et al., 2013; Sareen et al., 2013) of
C9ORF72 motor neuron pathology have been reported. While
each of these models have been instructive, it can be argued
that a more informative model will permit studies of the
C9ORF72-expanded GGGGCC repeats in the context of stable
expression in an intact mammalian nervous system. For that
reason, we have generated a novel transgenic mouse carrying
an expanded form of the human C9ORF72 gene with approxi-
mately 500 GGGGCC motifs.
RESULTS
BAC Transgenic Mice Express the Human Mutant
C9ORF72 Gene
We generated a line of SJL/B6 transgenic mice using a 153.2 kb
bacterial artificial chromosome containing exons 1 through 6 of
the human C9ORF72 with about 500 GGGGCC repeat motifs,
including approximately 140.5 kb of upstream sequence (Fig-
ure 1A; Figure S1A). Hemizygous C9BAC mice were viable, pro-
ducing progeny at expected Mendelian frequencies. Southern
blot analysis of genomic DNA from these animals detected two
distinct bands corresponding to about 500 and 300 GGGGCC
repeat motifs, which were intergenerational (Figure S1B) and tis-
sue-type stable (Figure 1B). Using a human-specific probe for all
variants (Vall), C9ORF72mRNA transcripts were detected in the
C9BACmice in all tissues examined (Figure S1C). The truncated
human C9ORF72 gene generates three transcript variants; V1
and V3 carry the repeat expansion (Figure S1A). Human-specific
probes targeting human C9ORF72 V1, V2, and V3 mRNAs de-
tected all three transcripts in the C9BAC mice at expression
levels relative to their abundances in human frontal cortex (Fig-
ure 1C). Moreover, the total level of the transgenic human tran-
scripts was roughly comparable to that of the endogenous
mouseC9ORF72 ortholog transcripts and to levels of expression
of human control and c9ALS/FTD cases (Figure 1C).
Survival, Motor, and Cognitive Systems Are Normal in
Mice Bearing the Mutant C9ORF72 Gene
A cohort of F1 generation male C9BAC mice was aged for
phenotypic characterization and analysis of survival. At all
ages, the C9BAC and control mice remained healthy. They
trended toward a non-significantly elevated weight compared
to non-transgenic (Ntg) littermates (Figure S1D) and lived beyond
2 years. Survival in the C9BAC and Ntg littermates was indistin-
guishable (Figure 1D).
We first tested for behavioral and histological abnormalities
within the motor system of the C9BAC mouse. Overall, the
C9BACmice showedno significantmotor deficits by rotarod per-
formance and grip strength testing (Figures S1E andS1F). No dif-
ference was observed in motor or sensory spinal nerve root axon
number and morphology (Figure S2A), nor was increased dener-
vation of neuromuscular junctions seen in 24-month-old C9BAC
mice (Figure S2B). Motor unit number estimation (MUNE)
recording in the hind limbs of 24-month-old C9BAC mice de-
tected no changes inMUNE score, motor unit size, or compound
motor action potential, although there was a trend toward a
modestly increased denervation score, as gauged by electromy-
ography (Figure 1E).We also assessed several pathological features in the motor
cortex and spinal cord that are common features of ALS. No sig-
nificant changes were seen in activation of microgliosis or astro-
gliosis (Figures S2C and S2E). Cytoplasmic mislocalization and
aggregation of TDP-43, both identified in the majority of ALS pa-
tients (Janssens and Van Broeckhoven, 2013; Rohrer et al.,
2015), were not detected in the motor cortex of our C9BAC
mice (Figures S2D and S2E). To assess activation of pro-
grammed cell death within the spinal cord, we observed levels
of cleaved capase-3 by western blotting; levels in C9BAC and
Ntg mice did not differ significantly (Figure S2F). Because
studies have demonstrated cortical hyperexcitability in ALS pa-
tients and cell lines with C9ORF72 hexanucleotide expansions
(Geevasinga et al., 2015), we next asked whether cortical
neurons of neonatal C9BAC mice showed altered electro-
physiological characteristics. We detected no changes in the
electrophysiological properties of either pyramidal tract-type or
intratelencephalically projecting neurons in L5 of motor cortex
of these neonatal C9BAC mice (Figures S2G–S2J; Table S1).
We next surveyed pathological findings that are common in
FTD. No activation of gliosis was detected in the prefrontal cor-
tex (PFC) or hippocampus (Figures S3A and S3B). Changes in
social interaction behavior have been described in rodent
models of FTD (Alfieri et al., 2014; Gascon et al., 2014); however,
we found no change in social behavior of adult C9BAC in
response to an intruder mouse assay. (Figure S3C). Quantitative
studies of Golgi preparations revealed no change in dendritic
spine density of PFC layer 2-3 pyramidal neuron apical dendrites
in aged C9BAC mice (Figure S3D). Finally, altered gene expres-
sion profiles have been shown in c9ALS/FTD patient-derived cell
lines (Donnelly et al., 2013; Lagier-Tourenne et al., 2013; Sareen
et al., 2013) and tissues (Prudencio et al., 2015). To determine
whether a specific C9ORF72 RNA profile can be defined in our
C9BAC transgenic mice, we sequenced total RNA extracted
from the frontal cortex of 6-month-old C9BAC mice and litter-
mate controls. Statistical analysis of differentially expressed
genes did not reveal any change between the two groups,
including several genes identified as differentially expressed in
induced pluripotent stem cell (iPSC)-derived motor neurons
(Donnelly et al., 2013; Sareen et al., 2013) (Figures S3E–S3H).
C9BACMice Recapitulate Histopathological Features of
Human C9ORF72 ALS-FTD
At autopsy, brains from c9ALS/FTD patients show several histo-
pathological characteristics that are not detected in other forms
of familial and sporadic ALS or FTD: (1) sense transcript nuclear
and occasional cytoplasmic RNA foci, (2) antisense transcript
nuclear RNA foci, and (3) the generation of DPR proteins through
RAN translation of the sense and antisense transcripts.
We used fluorescence in situ hybridization (FISH) to detect
C9ORF72 sense and antisense foci in the brain and spinal cord
of C9BACmice (Figure 2). Intranuclear, sense foci were detected
at 3 months of age (data not shown) and by 10 and 24 months
were abundant throughout the CNS, including motor cortex
and spinal cord (Figure 2A), present in both neurons (Figures
2B and 2C), and glia (Figure 2D). Antisense foci were also de-
tected in 10- and 24-month-old mice (Figure 2A) but were
more sparse throughout the brain than sense foci. QuantificationNeuron 88, 902–909, December 2, 2015 ª2015 Elsevier Inc. 903
Figure 1. Construct Design, Expansion Size, and Expression Profile for the C9ORF72 BAC Transgene and Phenotyping of C9BAC Mice
(A) Schematic of the bacterial artificial chromosome fragment used for generating the C9BAC mice. The 153.2 kb construct contains (as shown from left to right)
140.5 kb of human genomic DNA upstream ofC9ORF72, the humanC9ORF72 promoter region, and exons 1 to partial exon 6 with a (GGGGCC)500 repeat motif in
C9ORF72 intron 1. The black bar indicates the target region for the Southern blotting probe used in (B).
(B) Southern blot of genomic DNA extracted from various tissues digested with HindIII, SacI, and TaqI and probed with a 50-DIG-(GGGGCC)5-DIG-30 DNA probe.
Two bands of4.4 kb and6.0 kb are stable in size after six generations representing expansions of 300 and 500 repeats (see also Figure S1B). The arrowhead
indicates a non-specific band.
(C) ddPCR analysis of expression of all human C9ORF72 variants (Vall), and variants V1, V2, and V3 and the mouse C9ORF72 ortholog in human frontal cortex
tissues from non-neurological disease control, c9ALS/FTD and SOD fALS patients, and whole-brain homogenate from C9BAC and Ntg mice (mean ± SEM, n = 4,
Kruskal-Wallis test, Mann-Whitney U test, *p < 0.05, ND = not detectable).
(D) Kaplan-Meier curve representing lifespan showing no significant difference in survival of C9BACmice compared to Ntg littermates (Ntg n = 17, C9BAC n = 16,
Mandel-Cox Log Rank, p = 0.971).
(E) Physiological studies reveal showed no significant change in motor unit number estimations (MUNEs), motor units size, or compound motor action potential,
though a modest increase in electromyogram score was observed (mean ± SEM, Ntg n = 3, C9BAC n = 4 unpaired t test).of numbers of sense foci in nuclei of the cortical internal pyrami-
dal layer (layer V) (Figure 2E) and spinal motor neurons (Figure 2F)
revealed that the majority of foci-positive nuclei contain one to
five detectable sense foci, though in some cases greater than
20 foci were seen in individual nuclei. A trend toward a reduced
number of nuclei containing foci was seen between 10 and
24 months, reaching statistical significance in the motor cortex
internal pyramidal layer, but not spinal cord motor neurons.
Because both sense and antisenseC9ORF72 transcripts were
present in the C9BAC mice, we next sought evidence of RAN
translation products, using a sandwich immunoassay for the
detection of poly(Glycine-Proline) (poly(GP)), which is synthe-
sized from both sense and antisense transcripts. Tissues from904 Neuron 88, 902–909, December 2, 2015 ª2015 Elsevier Inc.4- and 24-month-old Ntg and C9BAC mice, and frontal cortex
from six c9ALS cases, were homogenized in buffer containing
2% SDS, with the detergent-soluble fraction analyzed for pol-
y(GP) content. At 4 months of age, poly(GP) was detected
throughout the brain of C9BAC mice, with levels highest in the
cerebellum, and also detected in the spinal cord, sciatic nerve,
and liver (Figure 2G). Though themean concentration of poly(GP)
levels in 4-month-old mice was lower than that observed in
c9ALS frontal cortex, the 4-month-old C9BAC mean did fall
within range of the lowest samples in the patient group (Fig-
ure 2G). All tissues from 24-month-old C9BAC mice showed a
significant reduction in SDS-soluble poly(GP) levels. One hy-
pothesis for the observed decline in soluble poly(GP) is that the
Figure 2. C9BAC Mice Recapitulate the Histopathological Hallmarks of C9ORF72 ALS and FTD Patients
(A) Fluorescence in situ hybridization (FISH) using Cy3-tagged DNA probes against sense and antisense abnormally expandedC9ORF72 transcripts (red, probe;
blue, DAPI nuclear stain). TheC9ORF72 repeat containing sense or antisense transcripts form intranuclear RNA inclusions, or foci, throughout the brain, including
motor cortex internal pyramidal layer and internal granular layer, and lumbar motor neurons of 24-month-old C9BAC mice.
(B–D) FISH coupled with cell-type-specific immunostaining revealed sense transcript foci in neurofilament heavy-positive neurons (B), choline acetyl transferase
(ChAT)-positive pyramidal neurons (C), and GFAP-positive astrocytes (D).
(E and F) The number of sense transcript foci per nucleus in 10-month- and 24-month-old C9BAC mice in (E) motor cortex internal pyramidal layer and (F)
lumbarmotor neuron nuclei (cortex: 10-month, n = 3, 821 nuclei; 24-month, n = 3, 845 nuclei: spinal cord: 10-month, n = 3, 124 nuclei; 24-month, n = 3, 100 nuclei:
mean ± SEM, two-way ANOVA, Bonferroni multiple comparison *p < 0.05, **p < 0.001).
(G) Quantification of soluble poly(GP) proteins in various regions of the CNS and liver of 4- and 24-month-old C9BAC mice and frontal cortex of c9ALS cases by
immunoassay (mean ± SEM, C9BAC groups n = 3, c9ALS n = 6, two-way ANOVA, Bonferroni’s multiple comparison, *p < 0.05, ***p < 0.001).
(H) Immunostaining for poly(GP) proteins in cortex of C9BAC mice. Staining revealed the presence of small perinuclear inclusion bodies throughout the brain at
10 months of age, with a pronounced elevation in the number observed in 24-month-old mice. Such inclusions were not observed in age-matched Ntg mice.
Scale bars: (A)–(D) = 10 mm; (H) = 20 mm.DPR proteins show an age-dependent propensity to form insol-
uble species. Immunostaining of brain tissues from 10- and
24-month-old C9BAC mice revealed the presence of small peri-
nuclear inclusion bodies stained for poly(GP) (Figure 2H). Such
inclusions were detected throughout the brain, including cortex,
cerebellum, and striatum, and were more frequently observed in
the brains of 24-month-old mice, suggesting a heightened depo-
sition of insoluble poly(GP) species.
We established primary cortical neuron cultures from C9BAC
and Ntg littermate embryos. At 10 days in vitro (DIV), both
nuclear foci containing sense or antisense C9ORF72 hexanu-
cleotide expansion transcripts (Figure 3A) and poly(GP) RAN
translation products could be detected (Figure 3B). We next
tested whether neurons from C9BAC mice are hypersensitiveto cellular stress. In a previous study, neuron-differentiated
iPSCs derived from FTD patients showed an increased sensi-
tivity to cell death induced by inhibition of autophagy in vitro (Al-
meida et al., 2013). We treated DIV15 primary cortical neuron
cultures derived from individual embryos with two inhibitors of
autophagy (Figure 3C), chloroquine and 3-methyladenine. Both
compounds increased cell death to the same degree in the
C9BAC and Ntg neurons, as determined by an LDH assay.
SilencingC9ORF72Transcripts andPoly(GP) Production
In Vitro
Though lacking cognitive or motor deficits, the C9BAC mouse
robustly recapitulates the molecular pathology of c9ALS/FTD,
with readily quantifiable expression of all three C9ORF72Neuron 88, 902–909, December 2, 2015 ª2015 Elsevier Inc. 905
Figure 3. Silencing of C9ORF72 in C9BAC
Mice and Primary Cortical Neurons
(A) Sense and antisense foci are detected in
cultured cortical neurons of C9BAC embryos at
10 days in vitro (DIV). These foci were not visible
following RNase treatment and were not detected
in Ntg neurons or by probes targeting themyotonic
dystrophy-associated type-1 (CTG)n or type-2
(CCTG)n expansions (DM1 and DM2, respectively,
scale bar = 5 mm).
(B) Concentration of poly(GP) in cultured cortical
neurons derived from individual C9BAC or Ntg
littermate embryos measured by immunoassay
(mean ± SEM, Ntg n = 2, C9BAC n = 6, unpaired
t test).
(C) No significant differences were detected in the
response of cultured cortical neurons derived from
individual C9BAC and Ntg embryos to the auto-
phagy inhibitors chloroquine or 3-methyladenine
(two independent experiments, individual embryos
cultured; C9BAC n = 6, Ntg n = 5, percent relative
to Ntg, mean ± SEM, two-way ANOVA, Bon-
ferroni’s multiple comparison, *p < 0.05).
(D) ddPCR analysis of all transcripts of C9ORF72
(Vall) relative to HPRT in two independent ex-
periments (Exp. 1. individual embryos n = 4,
mean ± SEM, one-way ANOVA, Bonferroni’s
multiple comparison test, *p < 0.05, ***p < 0.001;
Exp. 2. mixed embryo culture, n = 3, one-way
ANOVA, Bonferroni’s multiple comparison test,
***p < 0.001).
(E) Levels of the mature microRNA product
(normalized to snoRNA135) of rAAV-GFP-miRC9
trended toward correlation with percent silencing
of C9ORF72 relative to rAAV-GFP from Exp. 1
(black) and Exp. 2 (blue).
(F) Levels of poly(GP) quantified by immunoassay
from primary cortical neuron cultures derived
from two independent experiments (Exp. 1. indi-
vidual embryos n = 2, mean ± SEM, one-way
ANOVA; Exp. 2. mixed embryo culture, n = 3,
one-way ANOVA, Bonferroni’s multiple compari-
son test, **p < 0.01).transcripts, RNA foci and at least one of the poly(DP) RAN-trans-
lation products. Both of these readouts rely on the expression of
the C9ORF72 gene transcripts. We have therefore tested a gene
therapy approach to silence expression of the C9ORF72 tra-
nsgene in our C9BAC mice. We generated recombinant ad-
eno-associated virus (rAAV) serotype 9 expressing an artificial
microRNA (miR) targeting exon three of human C9ORF72 pre-
ceded by an eGFP reporter, under the transcriptional control of
the CB-promoter and CMV-enhancer (rAAV-GFP-miRC9). For
control groups, a vector expressing only the eGFP reporter
was used (rAAV-GFP). We carried out two sets of experiments
in DIV4 primary cortical neuron cultures (Figures 3D–3F). In the
first (Exp 1), individual cultures were generated from separate
C9BAC hemizygous embryos from the same litter of C9BAC
mice; in the second (Exp 2), all transgenic embryos from a
C9BAC litter were pooled to generate a mixed population of906 Neuron 88, 902–909, December 2, 2015 ª2015 Elsevier Inc.cortical neurons from multiple transgenic embryos. In both ex-
periments, at DIV10 transgene transcripts and poly(GP) were
reduced by expression of the GFP control vector alone, in
conjunction with some cell death; to account for this non-spe-
cific silencing, all silencing outcomes are normalized to this
GFP control. In all experiments, we consistently observed further
depletion ofC9ORF72 products in groups expressing the micro-
RNA. Relative to the rAAV-GFP group, C9ORF72 mRNA tran-
script (Figure 3D) expression in individual embryo cultures (Exp
1) was decreased by 35% by rAAV-GFP-miRC9 (n = 4, one-
way ANOVA, Bonferroni’s multiple comparison, p < 0.05) and
24% in the pooled embryo cultures in Exp 2 (not statistically
significant; n = 3, one-way ANOVA, Bonferroni’s multiple com-
parison). We detected mature miRNA only in the rAAV-GFP-
miRC9-treated cultures and found that the percent silencing
was proportional to levels of the expressed miRNA (Figure 3E).
In two cultures derived from individual embryos (Exp 1), rAAV-
GFP-miRC9 reduced levels of poly(GP) by 60% (Figure 3F).
In mixed cultures (Exp 2), poly(GP) was reduced by 73% relative
to GFP. Though not significant by one-way ANOVA (n = 3, Bon-
ferroni multiple comparison test), we note that in Exp 2 statistical
testing of the rAAV-GFP versus rAAV-GFP-miRC9 (independent
of the untreated group) detected a significant decrease in pol-
y(GP) levels (unpaired t test, p = 0.0008).
DISCUSSION
We report here a novel line of transgenic mice that harbor a
portion of the human C9ORF72 gene with an expanded
GGGGCC repeatmotif. Though themice do not develop an overt
motor phenotype, they recapitulate distinctive histopathological
features seen in c9ALS/FTD patients, including both sense and
antisense intranuclear RNA foci and the presence of RAN trans-
lated DPR proteins. These data indicate that the 300–500
GGGGCC repeat motifs are sufficient for the generation and
deposition of abnormal tracts of RNA and DPR proteins but
not to induce neurodegeneration. Why this is the case remains
unclear. Possibly the pathology, seen quite clearly at the molec-
ular level, is not sufficient to compromise motor neuron viability
within the lifespan of the mice. Alternatively, some other aspect
of the model may be required to induce motor pathology. For
example, if the pathology in humans entails sequestration of crit-
ical RNA binding proteins by intranuclear RNA aggregates, it is
possible that these proteins are more abundant in the mouse
and thus less prone to be titrated to insufficiency in the RNA
foci. Alternatively, it is possible that the DPR proteins are better
tolerated in some manner in the mouse. Of note, in this same
issue of Neuron, O’Rourke et al. report that an independently
generated BAC transgenic mouse carrying the full human
C9ORF72 gene with the disease-associated expansion also ex-
presses histopathological features of C9ORF72 without behav-
ioral abnormalities and neurodegeneration (O’Rourke et al.,
2015).
Two aspects of the histological findings in these mice are
intriguing. First, there were distinctly more cells containing sense
foci than antisense RNA foci. This is broadly analogous to data
fromhuman cortex (Mizielinska et al., 2013). It is also conceivable
that the relative paucity of antisense RNA foci reflects the struc-
ture of the human BAC in our mice, which contains the full
50 expanseof theC9ORF72 locusbut only extends throughexons
1–6 and thus might lack 30 regulatory regions necessary for
generating antisense foci. Also of interest in the C9BAC mice
were age-dependent changes in the abundance of RNA foci
and the levels of soluble RAN translated poly(GP) proteins. Our
data indicate that the numbers of intranuclear foci composed of
C9ORF72 RNA sense transcripts declined between 10 and
24 months, possibly reflecting an age-dependent increase in
clearance of these foci, reduced expression of the offending tran-
scripts with age, or loss of foci-containing cells.
There were also age-related shifts in the properties of poly(GP)
DPR proteins. In 4-month-old C9BAC mice, SDS-soluble pol-
y(GP) species were present at a concentration comparable to
levels detected in frontal cortex of some c9ALS patients. Soluble
poly(GP) levels in 24-month-old C9BAC mice were lower, achange that coincided with an increased presence of poly(GP)-
positive inclusions, suggesting conversion of soluble poly(GP)
into insoluble, aggregating species.
Finally, we note that although the C9BAC mouse does not
develop a discernible abnormal behavioral phenotype, the histo-
pathological and transcript variant expression profile matches
well with that of c9ALS/FTD patients. In successful experiments
in vivo and in vitro (Donnelly et al., 2013; Lagier-Tourenne et al.,
2013; Sareen et al., 2013), the C9ORF72 expression has been
reduced following treatment with antisense oligonucleotides
(ASOs). In the present study, we have conducted a proof-of-prin-
ciple experiment to test whether an artificial microRNA (miR)
targeting exon 3 of C9ORF72 delivered by recombinant adeno-
associated virus (rAAV) might offer an alternative therapeutic
strategy. With this intervention, primary cortical neuron cultures
from the C9BAC transgenic mice demonstrated a consistent
trend toward reduced expression of C9ORF72 transcripts and
decreased production of the poly(GP) DPR. These studies sug-
gest that this strategy (AAV-mediated delivery of an artificial
miR) merits further investigation and that these C9BAC mice
will be useful for assessing therapies that silence transcription
or RAN translation across the expanded GGGGCC repeats or
otherwise inhibit the formation of RNA foci and DPR proteins.
Combined with accurate analytical techniques to quantify levels
of aberrant RNA transcripts, RNA foci, and DPR proteins, the
C9BAC mouse will be of considerable use for investigating the
pathophysiology of C9ORF72-mediated neurodegeneration
and much needed therapeutic approaches.
EXPERIMENTAL PROCEDURES
Generation of C9ORF72 Transgenic Mice
A BAC library was generated from a familial FTD/ALS patient from a
C9ORF72-linked ALS/FTD pedigree. Transgenic animals (C9BAC) were pro-
duced using a BAC carrying a 153.2 kb genomic DNA fragment including
140.5 kb upstream of C9ORF72, exons 1 to exon 6 of the C9ORF72 gene,
including part of the 30 UTR of the short isoform V1 and 500 GGGGCC mo-
tifs between exons 1 and 2. The University of Massachusetts Medical
School Institutional Animal Care and Use Committee approved all experi-
ments involving animals.
Electrophysiological Recordings
MUNE electrophysiological recordings were as described (Xia et al., 2010).
Further details and description of whole-cell cortical neuron recordings are
described in the Supplemental Experimental Procedures.
Droplet Digital PCR
Frozen tissue samples were homogenized in a gentleMACS Dissociator (Milte-
nyi Biotec) before total RNA extraction with Trizol (Life Technologies). Reverse
transcription to cDNAwas performed using random hexamers andMultiScribe
reverse transcriptase (High capacity RNA-to-cDNA Kit, Life Technologies).
Droplet Digital PCR (ddPCR) was performed using ddPCR Supermix for
Probes the QX100 Droplet Digital PCR system (Bio-Rad).
Poly(GP) Immunoassay and Immunostaining
Immunostaining and immunoassay for poly(GP) dipeptides was performed as
published (Ash et al., 2013). (Details are in the Supplemental Experimental
Procedures.)
Human Tissues
Frozen frontal cortex tissues analyzed for for poly(GP) via ELISA assay were
obtained from the Brain Bank for Neurodegenerative Disorders at Mayo ClinicNeuron 88, 902–909, December 2, 2015 ª2015 Elsevier Inc. 907
in Jacksonville, Florida, which operates under protocols approved by the
Mayo Clinic Institutional Review Board, in accordance with Health Insurance
Portability and Accountability Act guidelines. Frozen frontal cortex tissues
for ddPCR were obtained from the UCLA Human Brain and Spinal Fluid
Resource center and University of Massachusetts and were collected under
protocols approved by the UMMS Institutional Review Board.
RNA Fluorescence In Situ Hybridization
Frozen sections were hybridized overnight at 55C with DNA probes against
C9ORF72 sense (GGCCCC) and antisense (GGGGCC) transcripts, with a
Cy3 50 end tag, followed by incubation with primary antibodies, followed by
Alexa Fluor 488-conjugated secondary antibodies as required.
RNA-Seq
RNA sequencing (RNA-seq) was performed on frontal cortex tissue of
6-month-old C9BAC mice and their Ntg littermates (see Supplemental Exper-
imental Procedures). RNA-seq data are deposited in the NCBI GEO repository
(GEO: GSE74973).
MicroRNA Design and Cloning
A 22-nucleotide artificial miRNA (targeting sequence 50-AATGCAGA-
GAGTGGTGCTATA-30) in exon 3 of the C9ORF72 gene was designed and
cloned into the miR-155 backbone. This artificial miR was cloned into the 30
UTR of a GFP encoding AAV proviral plasmid under the control of the chicken
beta actin (CB) promoter with a CMV enhancer. The plasmidwas used to pack-
age pseudotyped rAAV9 vectors. Plasmids and vectors can be requested for
academic use at http://www.umassmed.edu/muellerlab.
ACCESSION NUMBER
The accession number for the RNA-seq data reported in this paper is GEO:
GSE74973.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.neuron.2015.11.018.
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